It was effective in vitro against tumor B cells obtained from PBMC of CLL patients, and in vivo in mice and cynomolgus monkeys, causing complete B cell depletion in peripheral blood and lymphoid tissues also in the presence of a competitive anti-CD20 mAb (108). Here, MS4A1 is linked to B-cell chronic lymphocytic leukemia.